Study of Low Adherent Dressing Versus the Standard of Care for the Management of Skin Grafts Over Thermal Burns

NCT01654094 | Completed

• 2 other identifiers: MHP-P6-1W81XWH-10-2-0159
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 4

Brief Summary

The purpose of this study is to evaluate the P6 Low Adherent Study Dressing relative to the Standard of Care (SOC, Mafenide Acetate 5% Solution) for the management of skin grafts in burn wounds resulting from thermal burn injuries.

Conditions

Burns; Skin Burn Requiring Skin Graft

Outcome Measures

Primary Outcomes (1)

• Management of skin grafts as determined by investigator's visual assessment of percent graft take

  6 days

Secondary Outcomes (7)

• The incidence of post-operative graft infections

  15 days

• Assessment of patient's pain / discomfort, using a visual analog scale.

  15 days

• Costs of study burn site wound dressing regimens.

  15 days

• Ease of use and clinician preference of the study burn site wound dressing regimens

  15 days

• Statistical robustness of visual graft take assessments in-person and from digital photographs

  15 days

Study Arms (2)

P6 Low Adherent Dressing

EXPERIMENTAL

All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).

Device: P6 Low Adherent Dressing

Standard of Care (SOC)

ACTIVE COMPARATOR

All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).

Other: Standard of Care (SOC)

Interventions

P6 Low Adherent Dressing DEVICE

Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).

P6 Low Adherent Dressing

Standard of Care (SOC) OTHER

Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).

Standard of Care (SOC)

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have thermal burns from scalds, flame/fire or contact with a hot object.
• Patients must have a TBSA burn of less than or equal to 50%.
• Patients must have two nonadjacent study burn sites (i.e., separated in such a way that SOC dressing does not contaminate the study dressing) of comparable size (up to approximately 2% TBSA) and severity requiring excision and grafting.
• Patients must have undergone excision and autografting on or before post-burn day (PBD) 14.
• Patients' study burn sites will be treated with skin grafts with a mesh ratio up to 3:1, at the surgeon's discretion.
• Patients expected to be available for assessment of study burn sites at least until POD 6 ±1 day.
• Males or females at least 18 years of age but no older than 65 years of age at the time of informed consent.
• Patient and / or Legally Authorized Representative (LAR) voluntarily agrees to provide written informed consent and the willingness and ability to comply with all aspects of the protocol.

You may not qualify if:

• Patients with electrical or chemical burns.
• Patients with a study burn site excised and "grafted" with Integra.
• Patients with study burn sites on the buttocks, scalp, hands, feet, neck or ears.
• Patients taking vasopressors or inotropes.
• Patients using systemic immunosuppressants (e.g., corticosteroids and anti-neoplastic agents, etc.).
• Patients with acute renal failure, defined as creatinine clearance (CrCL) \>2.5 mg/dL or AKIN score greater than or equal to 2 or estimated GFR \< 30, if the assessment is conducted as part of the patient's routine clinical care.
• Patients with acute respiratory distress syndrome (ARDS), if the assessment is conducted as part of the patient's routine clinical care.
• Patients with liver cirrhosis (Childs-Pugh B Class or greater) or who have AST / ALT levels greater than or equal to 2 times the upper limit of theinstitution's normal range, if the assessment is conducted as part of the patient's routine clinical care.
• Patients with a known sensitivity or known intolerance to mafenide acetate (Sulfamylon) or to silver.
• Patients with any concurrent medical condition, which in the opinion of the investigator, may compromise their safety or the objectives of the study.
• Patients who are breastfeeding, pregnant or expecting to become pregnant during the study..
• Patients who have been exposed to an investigational drug or device within 30 days prior to Screening or is scheduled to receive another investigational drug or device during either the Treatment Phase or Follow-up Evaluation.

Sponsors & Collaborators

• Milliken Healthcare Products, LLC: lead
• Criterium, Inc.: collaborator
• U.S. Army Medical Research and Development Command: collaborator

Study Sites (4)

Shands at University of Florida

Gainesville, Florida, 32610, United States

Location

University of North Carolina, Chapel Hill

Chapel Hill, North Carolina, 27599, United States

Location

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States

Location

University of Tennessee Firefighter's Regional Burn Center

Memphis, Tennessee, 38103, United States

Location

MeSH Terms

Conditions

Burns

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Wounds and Injuries

Intervention Hierarchy (Ancestors)

Quality Indicators, Health Care; Quality of Health Care; Health Services Administration; Health Care Quality, Access, and Evaluation

Study Officials

• Bruce Cairns, MD

  University of North Carolina, Chapel Hill

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 24, 2012
• First Posted: July 31, 2012
• Study Start: October 1, 2012
• Primary Completion: September 1, 2014
• Study Completion: September 29, 2017
• Last Updated: October 2, 2017

Record last verified: 2017-09

Locations

US (4)